Compare iShares MSCI Hong Kong ETF (EWH) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Novartis AG — how do they compare? iShares MSCI Hong Kong ETF trades at $21.72 (market cap $1.16B), while Novartis AG trades at $142.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 231.5× iShares MSCI Hong Kong ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Novartis AG for 82 Days on average.
| EWH | NVS | |
|---|---|---|
Market Cap | $1.16B | $268.57B |
Volume | 3,176,523 | 1,532,573 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $168.62 |
52-Week Low | $20.66 | $121.80 |
Typical Hold Time | 61 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH trades at $21.58, down 0.19% with a bearish technical signal as moving averages show strong selling pressure. The ETF tracks Hong Kong's Hang Seng Index, which has faced significant volatility due to US-China tensions and Federal Reserve policy concerns. Recent institutional selling by Empowered Funds LLC (70.2% reduction in Q2 2026) reflects cautious sentiment toward Hong Kong markets.
Outlook remains challenged by geopolitical risks and Hong Kong market volatility, though oversold RSI levels suggest potential for near-term technical bounce. Key risks include continued US-China tensions and Fed policy uncertainty, while opportunities exist if Hong Kong equities stabilize. The ETF lacks fundamental metrics as it tracks an index rather than operating as a standalone company.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
